Do you want to know another role of ribonucleotide reductase M2?

September 18, 2012

Ribonucleotide reductase (RR) is a target metabolic enzymes for cancer therapy. Few studies have described the correlation between RRM2 and the development of colorectal cancer. And the possible mechanism by which RRM2 mediates colorectal cancer progression is unclear. It is well established that in some types of cancer, elevated RRM2 levels correlate with chemoresistance, but whether it may contribute to the response to ultraviolet irradiation is unclear.

Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. In addition, the incidence and mortality rates of colorectal cancer are on the rise. Recently, metabolic genes have received increasing and specific attention due to their potential role in carcinogenesis.

Previous studies have shown that alterations in ribonucleotide reductase (RR) levels may significantly influence the biological properties of cells, including tumor promotion and , suggesting that RR may be implicated in tumorigenesis. Recent findings have established that p53R2 suppresses the invasiveness of cancer cells, and its expression is associated with a better survival prognosis for CRC patients; however, the function of RRM2 in CRC is unclear. Here, we demonstrate that RRM2 may play an important role in the development of CRC and may contribute to the response to .

A research article to be published on September 14, 2012 in the addresses this question. The research team led by Prof. Lu from Shanghai Minimally Invasive Surgery Center (Ruijin Hospital, Shanghai Jiaotong University School of Medicine) from China investigated the roles of the hRRM2 subunit in colorectal cancer and UV-induced DNA damage repair.

The results showed that RRM2 overexpression was positively correlated with invasion depth, poorly differentiated type, and tumor, node, metastasis stage. The expression of RRM2 in HCT116 cells was down-regulated after transfection, and HCT116 cell proliferation was obviously suppressed. In the invasion test, the number of cells that passed through the chambers in the RRM2-siRNA group was lower than that in the negative control groups. The results suggest that RRM2 overexpression may be associated with colorectal . RRM2 silencing by siRNA may inhibit the hyperplasia and invasiveness of colorectal cancer cells, suggesting that RRM2 may play an important role in the infiltration and metastasis of colorectal cancer, which is a potential therapeutic strategy in colorectal cancer. In addition, RRM2 depletion increased UV sensitivity.

The researchers drew a conclusion that RRM2 may be a facilitating factor in colorectal tumorigenesis and UV-induced DNA damage repair.

Their study suggests that RRM2 silencing may inhibit the hyperplasia and invasiveness of colorectal . RRM2 may play an important role in the infiltration and metastasis of colorectal cancer and that suppression of its function could be a potential therapeutic strategy in .

More information: Lu AG, Feng H, Wang PXZ, Han DP, Chen XH, Zheng MH. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and UV-induced DNA damage repair. World J Gastroenterol 2012; 18(14): 4707-4713

Related Stories

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.